Hoth Therapeutics, Inc.
HOTH • Biotechnology
$0.85
▲ +0.05 (+6.08%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$13.42M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 4.72Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 15, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.85
Change6.08%
Shares Out15.79M
Market Cap$13.42M
Enterprise Value$9.38M
52W Range0.49 - 2.45
Beta0.53
P/E-1.15
P/B3.23
P/FCF-1.33
EV/EBITDA-0.81
EV/FCF-0.93
Price$0.85
Change6.08%
Shares Out15.79M
Market Cap$13.42M
Enterprise Value$9.38M
52W Range0.49 - 2.45
Beta0.53
P/E-1.15
P/B3.23
P/FCF-1.33
EV/EBITDA-0.81
EV/FCF-0.93
Earnings Yield-87.06%
FCF Yield-74.99%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio4.72
Quick Ratio4.72
Volume39.63K
Avg Volume8.12M
EPS Surprise-0.03
Investment DNA
How strong this company looks for long-term investors
46
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
85/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 4.72Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 4 analyst votes · 2026-10-20
100/100
Bullish
Bullish
4
Hold
0
Bearish
0
🧾
No insider activity
No recent insider transactions available.